Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers

Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers

Recent introduction of all-oral direct-acting antiviral (DAA) treatment has revolutionized care of patients with chronic hepatitis C virus (HCV) infection. Regrettably, the high cost of DAA treatment is burdensome for healthcare systems and may be prohibitive for some patients who would otherwise be...

Full description

Bibliographic Details
Main Authors: James A. Hutchinson, Kilian Weigand, Akinbami Adenugba, Katharina Kronenberg, Jan Haarer, Florian Zeman, Paloma Riquelme, Matthias Hornung, Norbert Ahrens, Hans J. Schlitt, Edward K. Geissler, Jens M. Werner
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-02-01
Series:Frontiers in Immunology
Subjects:
hepatitis C virus
direct-acting antiviral therapy
immune monitoring
biomarker
memory T cell
non-classical monocyte
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2018.00146/full

Similar Items

Similar Items